-
Posted by
Two Blokes Jul 16 -
Filed in
Stock
-
1 view
Bayer is a deep contrarian play, trading at less than 6x P/E, with potential for 100%+ upside if litigation risks subside. The main risks are ongoing glyphosate litigation and pharma pricing pressures, but current valuation heavily discounts these concerns. Despite crop science headwinds and legacy litigation, core pharma brands and pipeline growth provide a foundation for recovery.
